Clinical Trials
151 trialsBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Stanford University
Breast-48
University of Virginia
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
Thomas Jefferson University
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020
Vall d'Hebron Institute of Oncology
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
Sanofi
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
CAR T Cells in Mesothelin-Expressing Breast Cancer
University of Pennsylvania
Panthera
Cancer Trials Ireland
AM-003
University of Virginia
AMEERA-2
Sanofi
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Dana-Farber Cancer Institute
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
Massachusetts General Hospital
C4431001
Pfizer
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
MasterKey-01
Black Diamond Therapeutics, Inc.
STARLING
Turnstone Biologics, Corp.
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Tvardi Therapeutics, Incorporated
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
Accutar Biotechnology Inc
ARTHE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
NantBioScience, Inc.
AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy
Medical University of South Carolina
IPATunity150
Hoffmann-La Roche
PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
Pfizer
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
GlaxoSmithKline
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
MK-2206-015
Merck Sharp & Dohme LLC
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Kyowa Kirin Co., Ltd.
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Eisai Inc.
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Accutar Biotechnology Inc
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer
Boehringer Ingelheim
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Oncorus, Inc.
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Novartis
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Aileron Therapeutics, Inc.